DRD2 and schizophrenia: Impairments in the interplay among PSA-NCAM, dopamine D2 receptor, and TRPC1, −4, and −5 may lead to NCAM-and dopamine D2 receptor-associated psychiatric disorders, such as schizophrenia, bipolar disorder, depression, and anxiety disorder [6].